Bluebird bio, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (56)

Latest Posts

About This Stock More About This Stock
5 Of The Best-Performing Biotech Stocks Of 2017
Article By: Arpita Dutt
Sunday, December 31, 2017 3:46 PM EST
2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks.
In this article: XOMA, DVAX, SGMO, ALNY, BLUE, PFE, GILD
Read
E Large Cap Stocks: Gainers And Losers In 2017
Article By: Arie Goren
Saturday, December 30, 2017 12:24 PM EST
Here are the best and the worst performers among Russell 1000 stocks in 2017, and 20 stocks that have a chance to perform well in 2018, which should be another good year for investors in large cap stocks.
In this article: AN, LEN, OPK, RAD, RRC, UHS, ALNY, SBNY, EXAS, BLUE, ESNT, EVHC, SQ, UAA, OLED Also: IWB
Read
4 Biotech Stocks That More Than Doubled This Year
Article By: Zacks Investment Research
Saturday, December 23, 2017 7:50 PM EST
The biotech industry has been on the comeback trail in 2017 after facing challenges including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for key drugs.
In this article: JUNO, BLUE, XOMA, PBYI, PIRS, ALNY Also: CELG
Read
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Article By: Arpita Dutt
Monday, December 11, 2017 7:45 PM EST
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD
Read
Battleground: Analysts Diverge On Bluebird Bio Sickle Cell Risk
Article By: The Fly
Tuesday, October 3, 2017 9:55 PM EST
Wells Fargo's analyst Jim Birchenough is recommending buying the stock on weakness as he believes his Morgan Stanley peer's analysis of the company's LentiGlobin gene therapy program for Sickle Cell Disease is flawed.
In this article: BLUE Also: GILD
Read

PARTNER HEADLINES

Latest Tweets for $BLUE

No tweets yet!